ECSP22032851A - Inhibidores del fxia y m?todo de preparaci?n de los mismos y uso farmac?utico de los mismos - Google Patents

Inhibidores del fxia y m?todo de preparaci?n de los mismos y uso farmac?utico de los mismos

Info

Publication number
ECSP22032851A
ECSP22032851A ECSENADI202232851A ECDI202232851A ECSP22032851A EC SP22032851 A ECSP22032851 A EC SP22032851A EC SENADI202232851 A ECSENADI202232851 A EC SENADI202232851A EC DI202232851 A ECDI202232851 A EC DI202232851A EC SP22032851 A ECSP22032851 A EC SP22032851A
Authority
EC
Ecuador
Prior art keywords
same
preparation
pharmaceutical use
fxia
fxia inhibitors
Prior art date
Application number
ECSENADI202232851A
Other languages
English (en)
Inventor
Yinsuo Lu
Ying Xiao
Wei Xing
Junjun Wu
Jianli Wu
Zexin Hong
Original Assignee
Shenzhen Salubris Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Salubris Pharm Co Ltd filed Critical Shenzhen Salubris Pharm Co Ltd
Publication of ECSP22032851A publication Critical patent/ECSP22032851A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En la presente invenci?n se proporciona una serie de inhibidores selectivos del Factor XIa (FXIa), relacionados con el campo t?cnico de los f?rmacos qu?micos. La presente invenci?n tambi?n se refiere a composiciones farmac?uticas que contienen dichos compuestos y a un uso de dichos compuestos en medicamentos para el tratamiento de enfermedades como la tromboembolia.
ECSENADI202232851A 2019-09-27 2022-04-25 Inhibidores del fxia y m?todo de preparaci?n de los mismos y uso farmac?utico de los mismos ECSP22032851A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910923960 2019-09-27
CN201911318870 2019-12-19
CN202010902000 2020-09-01

Publications (1)

Publication Number Publication Date
ECSP22032851A true ECSP22032851A (es) 2022-08-31

Family

ID=75165578

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202232851A ECSP22032851A (es) 2019-09-27 2022-04-25 Inhibidores del fxia y m?todo de preparaci?n de los mismos y uso farmac?utico de los mismos

Country Status (14)

Country Link
US (1) US20230027295A1 (es)
EP (1) EP4036087A4 (es)
JP (1) JP7450024B2 (es)
KR (1) KR20220084301A (es)
CN (2) CN114206854B (es)
AU (1) AU2020355830B2 (es)
BR (1) BR112022005660A2 (es)
CA (1) CA3152667A1 (es)
CO (1) CO2022005082A2 (es)
EC (1) ECSP22032851A (es)
MX (1) MX2022003649A (es)
TW (1) TWI756848B (es)
WO (1) WO2021057818A1 (es)
ZA (1) ZA202202932B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115515938B (zh) * 2020-10-23 2024-05-10 深圳信立泰药业股份有限公司 FXIa抑制剂化合物的盐及其制备方法和医药用途
TW202227079A (zh) * 2020-10-23 2022-07-16 大陸商深圳信立泰藥業股份有限公司 ＦＸＩａ抑制劑化合物或其鹽的醫藥用途及含有其的藥物組合物
CN117480164B (zh) * 2020-12-11 2024-07-05 上海领泰生物医药科技有限公司 凝血因子XIa抑制剂及其制备方法和应用
TW202246219A (zh) * 2021-03-18 2022-12-01 大陸商深圳信立泰藥業股份有限公司 ＦＸＩａ抑制劑化合物雜質、其製備方法及其用途
CN116262740A (zh) * 2022-11-18 2023-06-16 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN116621742A (zh) * 2023-06-09 2023-08-22 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030396A1 (en) 1995-03-24 1996-10-03 Molecumetics Ltd. β-SHEET MIMETICS AND USE THEREOF AS PROTEASE INHIBITORS
ATE230414T1 (de) 1998-02-12 2003-01-15 Molecumetics Ltd Mimetika von beta-faltblatt und verfahren zur verwendung davon
AU2003243657A1 (en) 2002-06-26 2004-01-19 Bristol-Myers Squibb Company Amino-bicyclic pyrazinones and pyridinones
ES2365815T3 (es) * 2005-12-14 2011-10-11 Bristol-Myers Squibb Company Análogos de arilpropionamida, arilacrilamida, arilpropinamida o arilmetilurea como inhibidores del factor xia.
HUE034857T2 (en) 2011-10-14 2018-03-28 Bristol Myers Squibb Co Substituted tetrahydroisoquinoline compounds are inhibitors of factor XIA
TWI613199B (zh) * 2011-12-21 2018-02-01 小野藥品工業股份有限公司 化合物
GB2497806A (en) * 2011-12-21 2013-06-26 Ono Pharmaceutical Co Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
TWI633089B (zh) * 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
US9783530B2 (en) * 2014-05-28 2017-10-10 Merck Sharp & Dohme Corp. Factor Xla inhibitors
ES2694189T3 (es) * 2014-09-24 2018-12-18 Bayer Pharma Aktiengesellschaft Derivados de oxopiridina sustituidos
US10167280B2 (en) * 2014-09-24 2019-01-01 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
NO2721243T3 (es) * 2014-10-01 2018-10-20
JO3703B1 (ar) * 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
JP6785838B2 (ja) * 2015-08-05 2020-11-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 新規な置換グリシン誘導のｆｘｉａ阻害剤
CN107793396B (zh) * 2016-08-31 2021-02-26 江苏恒瑞医药股份有限公司 环氧基取代的氧代吡啶类衍生物、其制备方法及其在医药上的应用
KR102416718B1 (ko) * 2016-08-31 2022-07-05 지앙수 헨그루이 메디슨 컴퍼니 리미티드 옥소피콜린아미드 유도체, 이에 대한 제조 방법 및 이의 약학적 용도
US20190256474A1 (en) * 2016-10-26 2019-08-22 Proteostasis Therapeutics, Inc. N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis
TWI802654B (zh) * 2018-02-27 2023-05-21 大陸商江蘇恆瑞醫藥股份有限公司 一種酮基吡啶醯胺類衍生物的晶型及其製備方法

Also Published As

Publication number Publication date
KR20220084301A (ko) 2022-06-21
CN114206854A (zh) 2022-03-18
AU2020355830A9 (en) 2022-07-21
AU2020355830B2 (en) 2023-04-13
WO2021057818A1 (zh) 2021-04-01
JP2022550367A (ja) 2022-12-01
MX2022003649A (es) 2022-06-08
ZA202202932B (en) 2022-11-30
EP4036087A4 (en) 2023-09-20
BR112022005660A2 (pt) 2022-07-12
CN116120240A (zh) 2023-05-16
CN114206854B (zh) 2023-02-24
JP7450024B2 (ja) 2024-03-14
TW202112374A (zh) 2021-04-01
TWI756848B (zh) 2022-03-01
CA3152667A1 (en) 2021-04-01
CO2022005082A2 (es) 2022-05-20
AU2020355830A1 (en) 2022-03-31
US20230027295A1 (en) 2023-01-26
EP4036087A1 (en) 2022-08-03

Similar Documents

Publication Publication Date Title
ECSP22032851A (es) Inhibidores del fxia y m?todo de preparaci?n de los mismos y uso farmac?utico de los mismos
NI201800132A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2019001077A1 (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer.
PH12018502516A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
EA201890126A1 (ru) Новые бициклические производные, способ их получения и фармацевтические композиции, содержащие их
NI201800076A (es) Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen
ECSP17081744A (es) Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen
EA201890124A1 (ru) Новые гидроксикислотные производные, способ их получения и фармацевтические композиции, содержащие их
CL2018002718A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CU20220005A7 (es) Inhibidores tricíclicos de kars dependientes de akr1c3
CL2017001073A1 (es) 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos
CL2016002560A1 (es) Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación.
DOP2018000083A (es) NUEVOS DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CL2021000973A1 (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen.
UY35922A (es) Derivados de sulfonamidas tricíclicas
CO2022008313A2 (es) Compuestos químicos
ECSP18056196A (es) Derivados de indano
EA201650133A1 (ru) Твердые лекарственные формы тадалафила
PL407762A1 (pl) Nowe pochodne 9-fluorochino[3,2-b]benzo[1,4]tiazyny, sposób ich wytwarzania, zastosowanie do przygotowywania leków oraz zawierające je kompozycje farmaceutyczne i sposoby ich otrzymywania